187 related articles for article (PubMed ID: 34978715)
1. Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.
Abeykoon JP; Lasho TL; Dasari S; Rech KL; Ranatunga WK; Manske MK; Tischer A; Ravindran A; Young JR; Tobin WO; Flanagan EP; Nowakowski KE; Ruan GJ; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Patnaik MM; Wu X; Witzig TE; Goyal G; Go RS;
Am J Hematol; 2022 Mar; 97(3):293-302. PubMed ID: 34978715
[TBL] [Abstract][Full Text] [Related]
2. Erdheim-Chester disease.
Starkebaum G; Hendrie P
Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101510. PubMed ID: 32305313
[TBL] [Abstract][Full Text] [Related]
3. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
4. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
5. Erdheim-Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib.
Riancho JA; Hernández JL; González-Vela C; López-Sundh AE; González-Lopez MA; Gomez de la Fuente F; Quirce R; Diamond EL
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895147
[TBL] [Abstract][Full Text] [Related]
6. Erdheim-Chester Disease: a Concise Review.
Papo M; Emile JF; Maciel TT; Bay P; Baber A; Hermine O; Amoura Z; Haroche J
Curr Rheumatol Rep; 2019 Dec; 21(12):66. PubMed ID: 31807955
[TBL] [Abstract][Full Text] [Related]
7. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
Bhatia A; Hatzoglou V; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Yabe M; Petrova-Drus K; Panageas KS; Reiner A; Rosenblum M; Diamond EL
Neuro Oncol; 2020 Jul; 22(7):979-992. PubMed ID: 31950179
[TBL] [Abstract][Full Text] [Related]
8. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
9. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
[TBL] [Abstract][Full Text] [Related]
10. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases.
Alcedo PE; Gutierrez-Rodrigues F; Patel BA
Semin Hematol; 2022 Jul; 59(3):156-166. PubMed ID: 36115693
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis.
Dunn TN; Cope DI; Tang S; Sirupangi T; Parks SE; Liao Z; Yuan F; Creighton CJ; Masand RP; Alpuing Radilla L; Guan X; Detti L; Monsivais D; Matzuk MM
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38227801
[TBL] [Abstract][Full Text] [Related]
13. A case of suprasellar Erdheim-Chester disease and characterization of macrophage phenotype.
Kai K; Komohara Y; Shinojima N; Yano S; Mikami Y; Yokoo H; Mukasa A
J Clin Exp Hematop; 2020 Dec; 60(4):179-182. PubMed ID: 33028762
[TBL] [Abstract][Full Text] [Related]
14. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
16. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
17. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
Kanakis M; Petrou P; Lourida G; Georgalas I
Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
[TBL] [Abstract][Full Text] [Related]
18. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
19. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging.
Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP
J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983
[TBL] [Abstract][Full Text] [Related]
20. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
